A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib
Open Access
- 1 June 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (6) , e0198038
Abstract
There is a great unmet medical need in pancreatic carcinoma (PC) for novel drugs with other mechanisms of action than existing. PC cells express the onco-fetal RTK ROR1, absent on most normal post-partem cells. ROR1 is involved in proliferation, survival, EMT and metastasis of tumor cells in various malignancies. A small molecule inhibitor (KAN0439834) (530 Da) targeting the TK domain of ROR1 was developed and the activity in ROR1 expressing human PC cell lines (n = 8) evaluated. The effects were compared to a murine mAb against the external part of ROR1, gemcitabine, erlotinib and ibrutinib. KAN0439834 induced significant apoptosis of the tumor cells. EC50 values for KAN0439834 varied between 250–650 nM depending on the cell line. The corresponding values for erlotinib and ibrutinib were 10–40 folds higher. KAN0439834 was much more effective in inducing tumor cell death than the ROR1 mAb although both inhibited ROR1 phosphorylation and downstream non-canonical Wnt pathway molecules. Combination of KAN0439834 with erlotinib or ibrutinib had significant additive effects on tumor cell death. A first-in-class small molecule ROR1 inhibitor (KAN0439834) showed promising in vitro activity against a number of human PC cell lines. Interesting is the additive effects of erlotinib and ibrutinib which warrants further studies as both these agents are in clinical trials for pancreatic carcinoma.Keywords
Funding Information
- Svenska Forskningsrådet Formas (K2013-64X-21464-04-3)
- the Cancer and Allergy Foundation (150420 and 150122)
- the Cancer Society in Stockholm (144142, 164122)
- the Cancer Society in Stockholm (151313)
- The King Gustaf V Jubilee Fund (144193)
- the Swedish Cancer Society (140395, 150894, 160534)
- the Torsten Soderbergs Foundation
- AFA Försäkring (SE) (130054)
- The Karolinska Institutet Foundation
- The Karolinska Institutet Foundation
- The Karolinska Institutet Foundation
- The Stockholm County Council (20150070)
- The Felix Mindus Foundation
- VINNOVA (2015-01219)
- Kancera AB
This publication has 43 references indexed in Scilit:
- Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic CancerCurrent Pharmaceutical Design, 2013
- The Onco-Embryonic Antigen ROR1 Is Expressed by a Variety of Human CancersThe American Journal of Pathology, 2012
- Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of actionBreast Cancer Research, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cellsBritish Journal of Haematology, 2010
- Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancersOncology Letters, 2010
- The Role of Src in Solid TumorsThe Oncologist, 2009
- Ror receptor tyrosine kinases: orphans no moreTrends in Cell Biology, 2008
- Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapyInternational Journal of Cancer, 2008
- Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5aProceedings of the National Academy of Sciences, 2008